Refers to the number of clinical stage programs in proprietary cell therapy platforms.

No definition available.

Name:	btx_NumberOfClinicalStagePrograms
Namespace Prefix:	btx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Refers to the number of companies owned wholly or in part by the entity and accounted for under the equity method of investment.

+ References

No definition available.

+ Details

Name:	btx_NumberOfEquityMethodInvestments
Namespace Prefix:	btx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Refers to number of proprietary platform technologies of the entity's clinical programs.

+ References

No definition available.

+ Details

Name:	btx_NumberOfPlatformTechnologies
Namespace Prefix:	btx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Refers to the number of primary sectors targeted by the current clinical programs of the entity.

+ References

No definition available.

+ Details

Name:	btx_NumberOfPrimarySectors
Namespace Prefix:	btx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromMinorityShareholders
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=btx_AgeXTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Organization and Business Overview (Details) $ in Thousands		9 Months Ended
Organization and Business Overview (Details) $ in Thousands	Aug. 17, 2017 USD ($)	Sep. 30, 2017 USD ($) Sector Technology Subsidiary Program	Sep. 30, 2016 USD ($)
Organization and Business Overview [Abstract]
Number of primary sectors \| Sector		3
Number of platform technologies \| Technology		2
Number of subsidiaries \| Subsidiary		2
Number of clinical stage programs \| Program		3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from sale of common shares of subsidiary		$ 9,968	$ 0
AgeX Therapeutics, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from sale of common shares of subsidiary	$ 10,000
Ownership percentage	85.00%